Prophylactic and therapeutic effects of Recove Ointment on radiation induced dermatitis in breast cancer patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201204047136N2

Enrollment

Registered

2013-01-27

Start date

2012-08-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention (Recove(R) topical ointment): Patients undergoing radiotherapy will receive Recove ointment BD, for 25 sessions (5 days/week). Intervention 2: Control (Placebo ointment ba

Treatment - Drugs

Placebo

Intervention (Recove(R) topical ointment): Patients undergoing radiotherapy will receive Recove ointment BD, for 25 sessions (5 days/week)

Control (Placebo ointment base): Patients undergoing radiotherapy will receive petrolatum ointment BD, for 25 sessions (5 days/week)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: having diagnosed as having breast cancer; indication of radiotherapy and already underwent modified radical mastectomy. Exclusion criteria: Diabetes mellitus; Collagen vascular diseases; concurrent chemotherapy and history of chest wall radiation therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Dermatitis. Timepoint: Weekly. Method of measurement: According to RTOG scoring system.	—

Secondary

Measure	Time frame
Local adverse reaction. Timepoint: weekly. Method of measurement: physical exam.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEbrahim Zabihi

Research and technology affair - Babol University of Medical Sciences

e_zabihi@yahoo.com+98 11 1219 9596

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026